Bayer submits aflibercept 8 mg for marketing authorization in Japan

Berlin, March 1, 2023 – Bayer has submitted an application to the Japanese Ministry of Health, Labor, and Welfare (MHLW) seeking approval of aflibercept 8 mg for the treatment of two major retinal diseases, neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). The MHLW submission is based on positive results from both the phase III PULSAR trial in nAMD and the phase II/III PHOTON trial in DME…
Read More